myd88 homodimerization inhibitor peptide (Novus Biologicals)
Structured Review

Myd88 Homodimerization Inhibitor Peptide, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 103 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/set/MyD88+Inhibitor+Peptide+Set/pmc06735515-173-0-8
Average 94 stars, based on 103 article reviews
Images
1) Product Images from "Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial Sepsis"
Article Title: Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial Sepsis
Journal: Theranostics
doi: 10.7150/thno.37139
Figure Legend Snippet: The effect of MPLA mediated inflammatory preconditioning (InP) on cav-1 -/- mice. (A) Survival curves, n=8 mice per group. The mice were first given 0.1×10 8 CFUs E. coli , followed by the lethal dose of E. coli (3×10 8 CFUs) 2 h later,* vs. Saline. (B) Experimental procedures. (1) The WT mice were injected i.p. with 0.1×10 8 CFUs E. coli, and 2 h later were injected with 3×10 8 CFUs E. coli per mouse, and all 8 mice survived (InP). (2) C av-1 -/ - mice were injected i.p. with 0.1×10 8 E. coli, and 2 h later were injected with 3×10 8 CFUs E. coli, and all 8 mice died. (C) Intestine and liver tissues of mice stained with H&E. (D) ELISA of TNF-α/IL-6 in the supernatants of peripheral blood neutrophils in mice stimulated with 0.1×10 8 CFUs E. coli for 2 h. ** P <0.01 (Student's t test). (E) Western blot shows that InP did not promote translocation of TLR9 from cytosol to cell membrane in cav -/- mice. (F) Western blot shows significant reduction of endogenous Cav-1 by shRNA against Cav-1 (Cav-1 shRNA). (G) Immunoblot of TLR9, MyD88, TRAF3 and IRF3 in HL60 cells transfected Cav-1 shRNA and then stimulated with 0.1×10 8 CFUs E. coli for indicated times. Similar results were obtained in three independent experiments. (H) ELISA of TNF-α/IL-6 in the supernatants of HL60 cells transfected Cav-1 shRNA, stimulated with 0.1×10 8 CFUs E. coli for 2 h. ** P <0.01 (Student's t test).
Techniques Used: Saline, Injection, Staining, Enzyme-linked Immunosorbent Assay, Western Blot, Translocation Assay, Membrane, shRNA, Transfection
Figure Legend Snippet: Expression of TLR9-Cav-1 signaling proteins in the neutrophils of patients with sepsis. (A) Membrane TLR9 expression. (B) Cav-1 expression. (C) ROC curve for mTLR9. P <0.05. (D) ROC curve for Cav-1. P <0.05. (E) Association of Cav-1 with surface TLR9 expression in neutrophils. r2 =0.5791. (F) MyD88 expression. (G) TRAF3 expression. (H) IRF3 expression.
Techniques Used: Expressing, Membrane
Related Articles
Inhibition:Article Title: Characterization of the Inflammatory Response Evoked by Bacterial Membrane Vesicles in Intestinal Cells Reveals an RIPK2-Dependent Activation by Enterotoxigenic Escherichia coli Vesicles. Article Snippet: .. For inhibition assays, HT-29 cells (6 105 cells/well) were treated for 3 h with or without inhibitor for NOD1 (ML130; 10 mM) (Sigma-Aldrich), NOD2 (GSK717; 10 mM) (Sigma-Aldrich), Activity Assay:Article Title: SARS-CoV-2 activates the TLR4/MyD88 pathway in human macrophages: A possible correlation with strong pro-inflammatory responses in severe COVID-19 Article Snippet: In order to selectively block TLR4 signalling in cells, the inhibitor TAK-242 (Merck, 614316) was used at 10 μM [ ]. .. The angiotensin converting enzyme 2 (ACE2) activity inhibitor MLN-4760 (Merck, 530616) was employed at 10 μM [ ], the TLR3 inhibitor (R)-2-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-3-phenylpropanoic acid (Merck, 614310) at 30 μM [ ], the TIR-domain-containing adapter-inducing interferon-β (TRIF) inhibitor peptide (pepinh-TRIF, InvivoGen, tlrl-pitrif) at 5 μM (manufacturer's instruction), the Binding Assay:Article Title: SARS-CoV-2 activates the TLR4/MyD88 pathway in human macrophages: A possible correlation with strong pro-inflammatory responses in severe COVID-19 Article Snippet: In order to selectively block TLR4 signalling in cells, the inhibitor TAK-242 (Merck, 614316) was used at 10 μM [ ]. .. The angiotensin converting enzyme 2 (ACE2) activity inhibitor MLN-4760 (Merck, 530616) was employed at 10 μM [ ], the TLR3 inhibitor (R)-2-(3-Chloro-6-fluorobenzo[b]thiophene-2-carboxamido)-3-phenylpropanoic acid (Merck, 614310) at 30 μM [ ], the TIR-domain-containing adapter-inducing interferon-β (TRIF) inhibitor peptide (pepinh-TRIF, InvivoGen, tlrl-pitrif) at 5 μM (manufacturer's instruction), the |
